Limits...
Lipid disturbances in psoriasis: an update.

Pietrzak A, Michalak-Stoma A, Chodorowska G, Szepietowski JC - Mediators Inflamm. (2010)

Bottom Line: Its prevalence in the population is affected by genetic, environmental, viral, infectious, immunological, biochemical, endocrinological, and psychological factors, as well as alcohol and drug abuse.In the recent years, psoriasis has been recognised as a systemic disease associated with numerous multiorgan abnormalities and complications.Dyslipidemia is one of comorbidities in psoriatic patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Dermatology, Venereology and Paediatric Dermatology, Medical University of Lublin, ul. Radziwillowska 13, 20-080 Lublin, Poland.

ABSTRACT
Psoriasis is a common disease with the population prevalence ranging from 2% to 3%. Its prevalence in the population is affected by genetic, environmental, viral, infectious, immunological, biochemical, endocrinological, and psychological factors, as well as alcohol and drug abuse. In the recent years, psoriasis has been recognised as a systemic disease associated with numerous multiorgan abnormalities and complications. Dyslipidemia is one of comorbidities in psoriatic patients. Lipid metabolism studies in psoriasis have been started at the beginning of the 20th century and are concentrated on skin surface lipids, stratum corneum lipids and epidermal phospholipids, serum lipids, dermal low-density lipoproteins in the psoriatic skin, lipid metabolism, oxidative stress and correlations between inflammatory parameters, lipid parameters and clinical symptoms of the disease. On the basis of the literature data, psoriasis can be described as an immunometabolic disease.

Show MeSH

Related in: MedlinePlus

Influence of the psoriasis associated dyslipidemia on human organs. This figure is based (after permission) on the figure from [19].
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2914266&req=5

fig2: Influence of the psoriasis associated dyslipidemia on human organs. This figure is based (after permission) on the figure from [19].

Mentions: Nowadays the studies are concentrated on the skin surface lipids, epidermal lipids (including stratum corneum lipids, and epidermal phospholipids), serum lipids, dermal low-density lipoproteins in the psoriatic skin, lipid metabolism, oxidative stress and correlations between inflammatory parameters, lipid parameters, and clinical symptoms of the disease (Figure 2) [10–12, 16–19]. The aim of this study is to present an update of the lipid studies in psoriasis on the basis of the literature review.


Lipid disturbances in psoriasis: an update.

Pietrzak A, Michalak-Stoma A, Chodorowska G, Szepietowski JC - Mediators Inflamm. (2010)

Influence of the psoriasis associated dyslipidemia on human organs. This figure is based (after permission) on the figure from [19].
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2914266&req=5

fig2: Influence of the psoriasis associated dyslipidemia on human organs. This figure is based (after permission) on the figure from [19].
Mentions: Nowadays the studies are concentrated on the skin surface lipids, epidermal lipids (including stratum corneum lipids, and epidermal phospholipids), serum lipids, dermal low-density lipoproteins in the psoriatic skin, lipid metabolism, oxidative stress and correlations between inflammatory parameters, lipid parameters, and clinical symptoms of the disease (Figure 2) [10–12, 16–19]. The aim of this study is to present an update of the lipid studies in psoriasis on the basis of the literature review.

Bottom Line: Its prevalence in the population is affected by genetic, environmental, viral, infectious, immunological, biochemical, endocrinological, and psychological factors, as well as alcohol and drug abuse.In the recent years, psoriasis has been recognised as a systemic disease associated with numerous multiorgan abnormalities and complications.Dyslipidemia is one of comorbidities in psoriatic patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Dermatology, Venereology and Paediatric Dermatology, Medical University of Lublin, ul. Radziwillowska 13, 20-080 Lublin, Poland.

ABSTRACT
Psoriasis is a common disease with the population prevalence ranging from 2% to 3%. Its prevalence in the population is affected by genetic, environmental, viral, infectious, immunological, biochemical, endocrinological, and psychological factors, as well as alcohol and drug abuse. In the recent years, psoriasis has been recognised as a systemic disease associated with numerous multiorgan abnormalities and complications. Dyslipidemia is one of comorbidities in psoriatic patients. Lipid metabolism studies in psoriasis have been started at the beginning of the 20th century and are concentrated on skin surface lipids, stratum corneum lipids and epidermal phospholipids, serum lipids, dermal low-density lipoproteins in the psoriatic skin, lipid metabolism, oxidative stress and correlations between inflammatory parameters, lipid parameters and clinical symptoms of the disease. On the basis of the literature data, psoriasis can be described as an immunometabolic disease.

Show MeSH
Related in: MedlinePlus